Immunotherapy cocktail takes on tough throat cancer
NCT ID NCT07392320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immunotherapy drug (penpulimab) to standard chemotherapy and radiation, followed by maintenance immunotherapy, works better than the usual maintenance drug capecitabine for people with high-risk nasopharyngeal cancer. About 142 participants with advanced disease will be randomly assigned to one of two treatment groups. The goal is to see which approach better prevents the cancer from returning or spreading.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Penpulimab (immunotherapy drug) combined with chemotherapy (docetaxel, cisplatin) and radiation, compared to capecitabine (chemotherapy pill)
- What this could lead to
- If this works, it could offer a more effective treatment plan for high-risk nasopharyngeal cancer, potentially improving survival without the cancer coming back.
- What could go wrong
- This is a small, early-phase (Phase 2) trial, so results may not apply to everyone. Immunotherapy can cause immune-related side effects, and the added benefit over standard care is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HIGH-RISK NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antiseptic spray stop radiation burns in cancer patients?
- Second radiation may boost survival in returning throat cancer
- Low-Dose radiation plus immunotherapy shows promise for Tough-to-Treat nasopharyngeal cancer
- New combo therapy targets stubborn nasopharyngeal cancer in phase 3 trial
- Could delaying radiation be just as good for advanced nasopharyngeal cancer?
- New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types